...
首页> 外文期刊>Ophthalmology >Centrum use and progression of age-related cataract in the Age-Related Eye Disease Study: a propensity score approach. AREDS report No. 21.
【24h】

Centrum use and progression of age-related cataract in the Age-Related Eye Disease Study: a propensity score approach. AREDS report No. 21.

机译:年龄相关性眼病研究中的年龄相关性白内障的中心使用和进展:倾向评分法。 AREDS第21号报告。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To evaluate the effect of the multivitamin Centrum on the development and progression of age-related lens opacities. DESIGN: Clinic-based prospective cohort study. PARTICIPANTS: Four thousand five hundred ninety individuals with at least one natural lens and photographic follow-up (median, 6.3 years) were assessed for development or progression of lens opacities. MAIN OUTCOME MEASURES: Progression of "any" lens opacity or type-specific opacity was ascertained from lens photographs taken at baseline and at annual visits beginning at year 2. METHODS: The Age-Related Eye Disease Study (AREDS) showed no statistically significant effect of a high-dose antioxidant formulation on progression of lens opacities. Centrum also was provided to approximately two thirds of the study participants. Because Centrum use was elective, a logistic regression model of baseline characteristics was used to generate a propensity score for Centrum use. Repeated-measures logistic regression, adjusted for propensity score and other covariates, was used to evaluate associations of Centrum use and lens opacity. RESULTS: Centrum use, adjusted for propensity score and other covariates, was associated with a reduction in "any" lens opacity progression (odds ratio [OR] = 0.84, 95% confidence interval [CI] = 0.72-0.98, P = 0.025). Results for individual lens opacity types suggested that Centrum use was protective for nuclear opacity events (OR = 0.75, 95% CI = 0.61-0.91, P = 0.004). CONCLUSION: Observational data from the AREDS and other studies suggest that use of a multivitamin may delay the progression of lens opacities. A National Eye Institute-sponsored clinical trial scheduled for completion in 2007 will provide additional data on Centrum use and cataract development.
机译:目的:评估复合维生素Centrum对与年龄相关的晶状体混浊的发生和发展的影响。设计:基于临床的前瞻性队列研究。参与者:评估了至少有1个自然晶状体并进行了摄影随访(中位数为6.3年)的4,590名个体的晶状体混浊的发展或进展。主要观察指标:从基线和从第2年开始的年度随访中确定的晶状体照片确定“任何”晶状体混浊或特定类型的混浊的进展。方法:与年龄有关的眼疾研究(AREDS)没有统计学上的显着影响剂量的抗氧化剂制剂对晶状体混浊进展的影响。还向大约三分之二的研究参与者提供了Centrum。由于使用Centrum是可选的,因此使用基线特征的逻辑回归模型来生成使用Centrum的倾向得分。重复测量的逻辑回归(针对倾向评分和其他协变量进行了调整)用于评估使用Centrum和晶状体混浊的相关性。结果:针对倾向评分和其他协变量进行了调整的中心使用,与“任何”晶状体混浊度的降低相关(优势比[OR] = 0.84,95%置信区间[CI] = 0.72-0.98,P = 0.025) 。单个晶状体混浊类型的结果表明,使用Centrum可防止核混浊事件发生(OR = 0.75,95%CI = 0.61-0.91,P = 0.004)。结论:AREDS和其他研究的观察数据表明,使用多种维生素可能会延迟晶状体混浊的发展。一项由国家眼科研究所资助的临床试验计划于2007年完成,它将提供有关Centrum使用和白内障发展的更多数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号